International Task Force Recommends Warfarin Remain Mainstay for Antiphospholipid Syndrome
Rheumatology Network reports: Newly published recommendations from the Antiphospholipid Syndrome (APS) Treatment Trends Task Force suggests that rituximab and hydroxychloroquine may prove useful to treat APS but that vitamin K antagonists such as warfarin remain the mainstay of treatment. The publication resulted from discussions and presentations at the 14th International Congress on aPL (antiphospholipid antibodies) held in 2013.
Published paper: Erkan D Aguiar CL Andrade D Cohen H. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmunity Reviews (2014) 13: 685–696.